We are live on ! Find out more
EYEGW

Eyegate Pharmaceuticals, Inc. Warrants
EYEGW

Delisted

EYEGW was delisted on the 5th of August, 2020.

Back to rankings

3 hedge funds and large institutions have $8K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2020 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more capital invested

Capital invested by funds: $5K → $8K (+$3K)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$733

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$12
Name Holding Trade Value Shares
Change 		Change in
Stake
AIC
1
AWM Investment Company
New York
$6K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$2K +$733 +16,850 +90%
UBS Group
3
UBS Group
Switzerland
– -$12 -277 -7%

EYEGW Hedge Fund Activity: Q2 2020 in Review

3 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q2 2020, worth a combined $8K — up 60% from $5K a quarter earlier.

Fund positioning in EYEGW was balanced in Q2 2020: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $733. The largest seller was UBS Group, cutting an estimated $12.

  • 3 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q2 2020, unchanged from Q1 2020.
  • Funds reported $8K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q2 2020, up 60% quarter-over-quarter.
  • 0 funds opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q2 2020 and 0 closed out.
  • The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q2 2020 was Susquehanna International Group, an estimated $733 added.
  • The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q2 2020 was UBS Group, an estimated $12 sold.

Based on aggregated 13F filings for Q2 2020.